This company has been acquiredThe company may no longer be operating, as it has been acquired. Find out why through their latest events.See Latest EventsOpsens (OPSS.F) 주식 개요Opsens Inc. develops, manufactures, installs, and sells fiber optic sensors for cardiovascular interventions. 자세히 보기OPSS.F 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장4/6과거 실적0/6재무 건전성5/6배당0/6강점공정 가치 추정치보다 낮은 36.9% 에서 거래수익은 매년 64.05% 증가할 것으로 예상됩니다.위험 분석지난 1년 동안 주주가 희석되었습니다.지난 3개월 동안 주가 변동성이 US 시장과 비교해 높았습니다.모든 위험 점검 보기OPSS.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW490,690 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG490,690 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$2.1332.8% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-12m113m2016201920222025202620282031Revenue CA$112.7mEarnings CA$14.7mAdvancedSet Fair ValueView all narrativesOpsens Inc. 경쟁사ElectromedSymbol: NYSEAM:ELMDMarket cap: US$379.4mZynexSymbol: OTCPK:ZYXI.QMarket cap: US$1.7mPulmonxSymbol: NasdaqGS:LUNGMarket cap: US$62.1mSenseonics HoldingsSymbol: NasdaqGS:SENSMarket cap: US$279.3m가격 이력 및 성과Opsens 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$2.1352주 최고가CA$2.1452주 최저가CA$0.97베타0.321개월 변동3.01%3개월 변동55.12%1년 변동54.00%3년 변동147.17%5년 변동301.74%IPO 이후 변동690.33%최근 뉴스 및 업데이트공시 • Dec 13Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for approximately CAD 340 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately $253 million (CAD 345 million) at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction. On October 31, 2023, Québec Superior Court issued an interim order in connection with the transaction. On November 28, 2023, the applicable waiting period has expired under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and the applicable limitation period during which a notice of national security review could be issued under the Investment Canada Act(Canada) R.S.C., 1985, c. 28 (1st Supp.), as amended (the “ICA”) has expired without any such notice having been sent. As of December 1, 2023, shareholders of OpSens approved the transaction. Subject to receiving the final order of the Superior Court of Québec and satisfaction of customary closing conditions, it is currently expected that the Arrangement will be completed by mid-December 2023. the Superior Court of Québec issued a final order on December 8, 2023 and It is anticipated that the Arrangement will be completed on or about December 12, 2023, subject to the satisfaction of customary closing conditions. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share. Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and Robert Fonn and Ted Maduri of DLA Piper (Canada) LLP and Adam Ghander of DLA Piper LLP (US) as legal advisors. Piper Sandler & Co. served as OpSens' financial advisor, while Emmanuel Grondin and Renée Loiselle of Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. TSX Trust Company is the transfer agent and depositary of Opsens. Kingsdale Advisors is the proxy solicitation agent for Opsens. Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) on December 12, 2023. Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million (CAD 150 million) draw under its revolving credit facility. In connection with the closing of the transaction, OpSens’ common shares will cease trading in the public market and will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX.공시 • Oct 11Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction (the "Meeting"). Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and DLA Piper as legal advisor. Piper Sandler LLC served as OpSens' financial advisor, while Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share.공시 • Jul 07Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023Opsens Inc. announced that they will report Q3, 2023 results Pre-Market on Jul 13, 2023공시 • May 11OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR StudyOpSens Inc. announced SavvyWire inclusion in the COMPLETE TAVR clinical study to investigate the impact of standardized invasive hemodynamics (SIH) during transcatheter aortic valve replacement or TAVR procedures. COMPLETE TAVR, an Investigator Initiated Study sponsored by Edwards Lifesciences, will determine whether a strategy of complete revascularization involving staged percutaneous coronary intervention (PCI) using drug eluting stents to treat all suitable coronary artery lesions after successful balloon expandable TAVR, is superior to a strategy of medical therapy alone in reducing the composite outcome of cardiovascular death, new myocardial infarction, ischemia-driven revascularization or hospitalization for unstable angina or heart failure. The COMPLETE TAVR study is a randomized, multicenter, open-label trial with blinded adjudication of outcomes with planned enrollment of 4,000 patients at up to 120 centers. The SIH sub-study using the SavvyWire will enroll up to 200 patients at up to 20 centers across the United States and Canada. The SIH sub-study using SavvyWire has already started enrollment, and is anticipated to be completed later in 2023, with results anticipated early in 2024. Dr. Wood will provide updates on the progress of the study as more data becomes available. SavvyWire is more than a wire, as the world's first and only sensor-guided TAVR solution. It uniquely provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.공시 • Jan 06Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023Opsens Inc. announced that they will report Q1, 2023 results Pre-Market on Jan 12, 2023공시 • Nov 08Opsens Inc., Annual General Meeting, Jan 24, 2023Opsens Inc., Annual General Meeting, Jan 24, 2023.더 많은 업데이트 보기Recent updates공시 • Dec 13Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for approximately CAD 340 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately $253 million (CAD 345 million) at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction. On October 31, 2023, Québec Superior Court issued an interim order in connection with the transaction. On November 28, 2023, the applicable waiting period has expired under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and the applicable limitation period during which a notice of national security review could be issued under the Investment Canada Act(Canada) R.S.C., 1985, c. 28 (1st Supp.), as amended (the “ICA”) has expired without any such notice having been sent. As of December 1, 2023, shareholders of OpSens approved the transaction. Subject to receiving the final order of the Superior Court of Québec and satisfaction of customary closing conditions, it is currently expected that the Arrangement will be completed by mid-December 2023. the Superior Court of Québec issued a final order on December 8, 2023 and It is anticipated that the Arrangement will be completed on or about December 12, 2023, subject to the satisfaction of customary closing conditions. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share. Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and Robert Fonn and Ted Maduri of DLA Piper (Canada) LLP and Adam Ghander of DLA Piper LLP (US) as legal advisors. Piper Sandler & Co. served as OpSens' financial advisor, while Emmanuel Grondin and Renée Loiselle of Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. TSX Trust Company is the transfer agent and depositary of Opsens. Kingsdale Advisors is the proxy solicitation agent for Opsens. Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) on December 12, 2023. Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million (CAD 150 million) draw under its revolving credit facility. In connection with the closing of the transaction, OpSens’ common shares will cease trading in the public market and will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX.공시 • Oct 11Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction (the "Meeting"). Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and DLA Piper as legal advisor. Piper Sandler LLC served as OpSens' financial advisor, while Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share.공시 • Jul 07Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023Opsens Inc. announced that they will report Q3, 2023 results Pre-Market on Jul 13, 2023공시 • May 11OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR StudyOpSens Inc. announced SavvyWire inclusion in the COMPLETE TAVR clinical study to investigate the impact of standardized invasive hemodynamics (SIH) during transcatheter aortic valve replacement or TAVR procedures. COMPLETE TAVR, an Investigator Initiated Study sponsored by Edwards Lifesciences, will determine whether a strategy of complete revascularization involving staged percutaneous coronary intervention (PCI) using drug eluting stents to treat all suitable coronary artery lesions after successful balloon expandable TAVR, is superior to a strategy of medical therapy alone in reducing the composite outcome of cardiovascular death, new myocardial infarction, ischemia-driven revascularization or hospitalization for unstable angina or heart failure. The COMPLETE TAVR study is a randomized, multicenter, open-label trial with blinded adjudication of outcomes with planned enrollment of 4,000 patients at up to 120 centers. The SIH sub-study using the SavvyWire will enroll up to 200 patients at up to 20 centers across the United States and Canada. The SIH sub-study using SavvyWire has already started enrollment, and is anticipated to be completed later in 2023, with results anticipated early in 2024. Dr. Wood will provide updates on the progress of the study as more data becomes available. SavvyWire is more than a wire, as the world's first and only sensor-guided TAVR solution. It uniquely provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.공시 • Jan 06Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023Opsens Inc. announced that they will report Q1, 2023 results Pre-Market on Jan 12, 2023공시 • Nov 08Opsens Inc., Annual General Meeting, Jan 24, 2023Opsens Inc., Annual General Meeting, Jan 24, 2023.주주 수익률OPSS.FUS Medical EquipmentUS 시장7D0.2%-1.3%0.7%1Y54.0%-18.6%20.6%전체 주주 수익률 보기수익률 대 산업: OPSS.F은 지난 1년 동안 -18.6%의 수익을 기록한 US Medical Equipment 산업보다 더 좋은 성과를 냈습니다.수익률 대 시장: OPSS.F은 지난 1년 동안 20.6%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.주가 변동성Is OPSS.F's price volatile compared to industry and market?OPSS.F volatilityOPSS.F Average Weekly Movement15.1%Medical Equipment Industry Average Movement8.5%Market Average Movement7.3%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.2%안정적인 주가: OPSS.F의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: OPSS.F의 주간 변동성은 지난 1년간 10%에서 15%로 증가했습니다.회사 소개설립직원 수CEO웹사이트2003293Louis Laflammeopsens.com더 보기Opsens Inc. 기초 지표 요약Opsens의 순이익과 매출은 시가총액과 어떻게 비교됩니까?OPSS.F 기초 통계시가총액US$247.03m순이익 (TTM)-US$9.12m매출 (TTM)US$35.57m6.9x주가매출비율(P/S)-27.1x주가수익비율(P/E)OPSS.F는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표OPSS.F 손익계산서 (TTM)매출CA$48.35m매출원가CA$20.37m총이익CA$27.97m기타 비용CA$40.38m순이익-CA$12.40m최근 보고된 실적Aug 31, 2023다음 실적 발표일해당 없음주당순이익(EPS)-0.11총이익률57.86%순이익률-25.65%부채/자본 비율5.4%OPSS.F의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/12/13 17:31종가2023/12/12 00:00수익2023/08/31연간 수익2023/08/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Opsens Inc.는 6명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관David MartinBloom Burton & Co.Jeffrey CohenLadenburg Thalmann & CompanyCorey HammillParadigm Capital, Inc.3명의 분석가 더 보기
공시 • Dec 13Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for approximately CAD 340 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately $253 million (CAD 345 million) at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction. On October 31, 2023, Québec Superior Court issued an interim order in connection with the transaction. On November 28, 2023, the applicable waiting period has expired under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and the applicable limitation period during which a notice of national security review could be issued under the Investment Canada Act(Canada) R.S.C., 1985, c. 28 (1st Supp.), as amended (the “ICA”) has expired without any such notice having been sent. As of December 1, 2023, shareholders of OpSens approved the transaction. Subject to receiving the final order of the Superior Court of Québec and satisfaction of customary closing conditions, it is currently expected that the Arrangement will be completed by mid-December 2023. the Superior Court of Québec issued a final order on December 8, 2023 and It is anticipated that the Arrangement will be completed on or about December 12, 2023, subject to the satisfaction of customary closing conditions. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share. Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and Robert Fonn and Ted Maduri of DLA Piper (Canada) LLP and Adam Ghander of DLA Piper LLP (US) as legal advisors. Piper Sandler & Co. served as OpSens' financial advisor, while Emmanuel Grondin and Renée Loiselle of Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. TSX Trust Company is the transfer agent and depositary of Opsens. Kingsdale Advisors is the proxy solicitation agent for Opsens. Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) on December 12, 2023. Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million (CAD 150 million) draw under its revolving credit facility. In connection with the closing of the transaction, OpSens’ common shares will cease trading in the public market and will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX.
공시 • Oct 11Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction (the "Meeting"). Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and DLA Piper as legal advisor. Piper Sandler LLC served as OpSens' financial advisor, while Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share.
공시 • Jul 07Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023Opsens Inc. announced that they will report Q3, 2023 results Pre-Market on Jul 13, 2023
공시 • May 11OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR StudyOpSens Inc. announced SavvyWire inclusion in the COMPLETE TAVR clinical study to investigate the impact of standardized invasive hemodynamics (SIH) during transcatheter aortic valve replacement or TAVR procedures. COMPLETE TAVR, an Investigator Initiated Study sponsored by Edwards Lifesciences, will determine whether a strategy of complete revascularization involving staged percutaneous coronary intervention (PCI) using drug eluting stents to treat all suitable coronary artery lesions after successful balloon expandable TAVR, is superior to a strategy of medical therapy alone in reducing the composite outcome of cardiovascular death, new myocardial infarction, ischemia-driven revascularization or hospitalization for unstable angina or heart failure. The COMPLETE TAVR study is a randomized, multicenter, open-label trial with blinded adjudication of outcomes with planned enrollment of 4,000 patients at up to 120 centers. The SIH sub-study using the SavvyWire will enroll up to 200 patients at up to 20 centers across the United States and Canada. The SIH sub-study using SavvyWire has already started enrollment, and is anticipated to be completed later in 2023, with results anticipated early in 2024. Dr. Wood will provide updates on the progress of the study as more data becomes available. SavvyWire is more than a wire, as the world's first and only sensor-guided TAVR solution. It uniquely provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.
공시 • Jan 06Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023Opsens Inc. announced that they will report Q1, 2023 results Pre-Market on Jan 12, 2023
공시 • Nov 08Opsens Inc., Annual General Meeting, Jan 24, 2023Opsens Inc., Annual General Meeting, Jan 24, 2023.
공시 • Dec 13Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS).Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for approximately CAD 340 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately $253 million (CAD 345 million) at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction. On October 31, 2023, Québec Superior Court issued an interim order in connection with the transaction. On November 28, 2023, the applicable waiting period has expired under the United States Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) and the applicable limitation period during which a notice of national security review could be issued under the Investment Canada Act(Canada) R.S.C., 1985, c. 28 (1st Supp.), as amended (the “ICA”) has expired without any such notice having been sent. As of December 1, 2023, shareholders of OpSens approved the transaction. Subject to receiving the final order of the Superior Court of Québec and satisfaction of customary closing conditions, it is currently expected that the Arrangement will be completed by mid-December 2023. the Superior Court of Québec issued a final order on December 8, 2023 and It is anticipated that the Arrangement will be completed on or about December 12, 2023, subject to the satisfaction of customary closing conditions. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share. Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and Robert Fonn and Ted Maduri of DLA Piper (Canada) LLP and Adam Ghander of DLA Piper LLP (US) as legal advisors. Piper Sandler & Co. served as OpSens' financial advisor, while Emmanuel Grondin and Renée Loiselle of Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. TSX Trust Company is the transfer agent and depositary of Opsens. Kingsdale Advisors is the proxy solicitation agent for Opsens. Haemonetics Corporation (NYSE : HAE) completed the acquisition of Opsens Inc. (TSX : OPS) on December 12, 2023. Haemonetics financed the acquisition through a combination of cash-on-hand and a $110 million (CAD 150 million) draw under its revolving credit facility. In connection with the closing of the transaction, OpSens’ common shares will cease trading in the public market and will be delisted from the Toronto Stock Exchange and withdrawn from the OTCQX.
공시 • Oct 11Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million.Haemonetics Corporation (NYSE : HAE) entered into a definitive agreement to acquire Opsens Inc. (TSX : OPS) for CAD 345 million on October 10, 2023. Haemonetics will acquire all outstanding shares of OpSens for CAD $2.90 per share in an all-cash transaction representing a fully diluted equity value of approximately USD $253 million at current exchange rate. Haemonetics plans to finance this acquisition through a combination of cash and a revolving credit facility. Following this acquisition, Haemonetics' net debt to EBITDA ratio, per the terms set forth in the Company's existing Credit Agreement, is expected to be approximately 2.1x. The transaction will be affected by way of an arrangement under the Business Corporations Act (Québec). The transaction is expected to close by the end of January 2024. Completion of the acquisition is subject to the approval of OpSens shareholders, receipt of court and regulatory approval, as well as certain other closing conditions customary for transactions of this nature. OpSens' board of directors (the "Board") unanimously approved the Transaction and recommends that holders of Shares (the "Shareholders") vote in favour of the Transaction. The process and negotiation of the Transaction were supervised by a special committee of OpSens' Board (the "Special Committee"). Both the Board and the Special Committee determined, after receiving the fairness opinions of Piper Sandler & Co. ("Piper Sandler") and PricewaterhouseCoopers LLP ("PwC") and financial and legal advice, that the Transaction is in the best interests of the Corporation and is fair and reasonable to Shareholders. The Board also unanimously recommends that Shareholders vote in favour of the Transaction at the special meeting of Shareholders to be called to approve the Transaction (the "Meeting"). Goldman Sachs & Co. LLC served as financial advisor for Haemonetics and DLA Piper as legal advisor. Piper Sandler LLC served as OpSens' financial advisor, while Norton Rose Fulbright served as its legal advisor. PwC is acting as independent financial advisor to the Special Committee. The transaction is expected to be immediately accretive to Haemonetics' revenue growth. On a GAAP basis, Haemonetics expects this transaction to be slightly dilutive to earnings per diluted share in fiscal year 2024 due to transaction and integration costs and accretive thereafter. Haemonetics expects this transaction to be immediately accretive to adjusted earnings per diluted share.
공시 • Jul 07Opsens Inc. to Report Q3, 2023 Results on Jul 13, 2023Opsens Inc. announced that they will report Q3, 2023 results Pre-Market on Jul 13, 2023
공시 • May 11OpSens Inc. Announces Inclusion of Savvywire™ in COMPLETE TAVR StudyOpSens Inc. announced SavvyWire inclusion in the COMPLETE TAVR clinical study to investigate the impact of standardized invasive hemodynamics (SIH) during transcatheter aortic valve replacement or TAVR procedures. COMPLETE TAVR, an Investigator Initiated Study sponsored by Edwards Lifesciences, will determine whether a strategy of complete revascularization involving staged percutaneous coronary intervention (PCI) using drug eluting stents to treat all suitable coronary artery lesions after successful balloon expandable TAVR, is superior to a strategy of medical therapy alone in reducing the composite outcome of cardiovascular death, new myocardial infarction, ischemia-driven revascularization or hospitalization for unstable angina or heart failure. The COMPLETE TAVR study is a randomized, multicenter, open-label trial with blinded adjudication of outcomes with planned enrollment of 4,000 patients at up to 120 centers. The SIH sub-study using the SavvyWire will enroll up to 200 patients at up to 20 centers across the United States and Canada. The SIH sub-study using SavvyWire has already started enrollment, and is anticipated to be completed later in 2023, with results anticipated early in 2024. Dr. Wood will provide updates on the progress of the study as more data becomes available. SavvyWire is more than a wire, as the world's first and only sensor-guided TAVR solution. It uniquely provides a 3-in-1 solution for stable aortic valve delivery and positioning, continuous accurate hemodynamic measurement during the procedure, and reliable left ventricular pacing without the need for adjunct devices or venous access.
공시 • Jan 06Opsens Inc. to Report Q1, 2023 Results on Jan 12, 2023Opsens Inc. announced that they will report Q1, 2023 results Pre-Market on Jan 12, 2023
공시 • Nov 08Opsens Inc., Annual General Meeting, Jan 24, 2023Opsens Inc., Annual General Meeting, Jan 24, 2023.
